南新制药终止重大资产重组

Core Points - Nanjing Pharmaceutical (688189) announced the termination of its major asset restructuring plan [2] - The company had previously signed a letter of intent to acquire assets from Future Pharmaceutical, which includes three entities [2] - Despite multiple discussions and negotiations regarding the feasibility and core terms of the transaction, the parties could not reach an agreement [2] - To protect the interests of the company and its shareholders, all parties agreed to terminate the transaction and signed a termination agreement [2]